IconOVir Bio, Inc.

IconOVir Bio, Inc. is a biopharmaceutical company focused on developing innovative therapies to treat cancer and improve patient quality of life through advanced oncolytic virotherapy. Founded in 2018 and headquartered in San Diego, US, IconOVir Bio, Inc. specializes in creating therapies that target cancer cells using engineered viruses.

The company has not undergone significant pivots or changes in its operations. Mark McCamish serves as the CEO. The company raised USD 77 mn in its Series A funding round on December 1, 2020, with major investments from Bellco Capital, GV, Logos Capital, Nextech, Polaris Partners, Two River, Vida Ventures, and Wellington Management, totaling USD 77 mn raised to date. IconOVir specializes in developing innovative therapeutic solutions aimed at curing cancer and enhancing the quality of life for patients globally.

The company's core product offerings include advanced biopharmaceuticals designed to target and eliminate cancer cells while minimizing side effects. These therapies utilize technology in oncolytic virotherapy, harnessing engineered viruses to selectively infect and destroy tumor cells. The primary end users of these products are cancer patients, while healthcare providers and oncologists represent the client base administering these therapies. IconOVir’s products are distributed across multiple geographical markets, including the United States, Europe, and select regions in Asia, catering to a diverse patient population seeking innovative cancer treatments.

IconOVir generates revenue through direct-to-consumer sales and strategic partnerships with healthcare institutions. The transaction structure includes sales of its biopharmaceutical products to hospitals and clinics, enabling them to offer advanced cancer treatments. Customers engage in bulk purchases and may enter into long-term agreements, facilitating consistent revenue streams. The pricing reflects the advanced technology and efficacy of the treatments, aligning with industry standards for specialized biopharmaceuticals, ensuring accessibility for end users and fostering long-term relationships with committed healthcare providers.

IconOVir plans to leverage the recent Series A funding of USD 77 mn raised in December 2020 to support the development of new products and expand into new markets. The company aims to design and launch additional therapies targeting specific cancer types over the next few years. Furthermore, plans are in place to enter emerging markets in Asia and parts of Europe by 2023, with a focus on increasing access to their innovative treatments.